Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study

被引：6

作者：

Anty, R. ^{[1
,2
]}

Favre, G. ^{[3
,4
]}

Coilly, A. ^{[5
]}

Rossignol, E. ^{[6
,7
]}

Houssel-Debry, P. ^{[6
]}

Duvoux, C. ^{[8
]}

De Ledinghen, V ^{[9
]}

Di Martino, V ^{[10
]}

Leroy, V ^{[11
]}

Radenne, S. ^{[12
]}

Komar, N. ^{[13
]}

Canva, V ^{[14
]}

D'Alteroche, L. ^{[15
]}

Durand, F. ^{[16
]}

Dumortier, J. ^{[17
]}

Lebray, P. ^{[18
]}

Besch, C. ^{[19
]}

Tran, A. ^{[1
,2
]}

Canivet, C. M. ^{[1
,2
]}

Botta-Fridlund, D. ^{[20
]}

Montialoux, H. ^{[21
]}

Moreno, C. ^{[22
]}

Conti, F.

Silvain, C. ^{[23
]}

Perre, P. ^{[24
]}

Habersetzer, F. ^{[25
]}

Abergel, A. ^{[26
]}

Debette-Gratien, M. ^{[27
]}

Dharancy, S. ^{[14
]}

Esnault, V. L. M. ^{[3
,4
]}

Fougerou-Leurent, C.

Cagnot, C. ^{[28
]}

Diallo, A. ^{[29
]}

Veislinger, A. ^{[6
,7
]}

Danjou, H. ^{[6
,7
]}

Samuel, D. ^{[5
]}

Pageaux, G-P ^{[29
]}

Duclos-Vallee, J-C ^{[5
]}

机构：

[1] Ctr Hosp Univ Nice, Pole Reference Hepatite C, Nice, France

[2] Hepat Complicat Obes, U1065, Team 8, Nice, France

[3] Serv Nephrol Dialyses Transplantat, Nice, France

[4] Univ Cote Azur, Fac Med, Lab Physiomed Mol, CNRS,UMR 7370, Nice, France

[5] Paris Sud Univ Hosp, AP HP, Paul Brousse Hosp, DHU Hepatinov Villejuif, Villejuif, France

[6] Rennes Univ Hosp, Pontchaillou Hosp, Rennes, France

[7] INSERM, CIC 1414, Rennes, France

[8] Henry Mondor Hosp, AP HP, Creteil, France

[9] Bordeaux Univ Hosp, Haut Leveque Hosp, INSERM, U1053, Bordeaux, France

[10] Besancon Univ Hosp, Jean Minjoz Hosp, Besancon, France

[11] Grenoble Univ Hosp, Albert Michallon Hosp, Grenoble, France

[12] Croix Rousse Hosp, HCL, Lyon, France

[13] Toulouse Univ Hosp, Toulouse, France

[14] Hop Huriez, Serv Hepatol, Lille, France

[15] Tours Univ Hosp, Tours, France

[16] Beaujon Hosp, AP HP, Clichy, France

[17] Hop Edouard Herriot, HCL, Lyon, France

[18] Pitie Salpetriere, AP HP, Paris, France

[19] Strasbourg Univ Hosp, Strasbourg, France

[20] Marseille Univ Hosp, La Conception Hosp, Marseille, France

[21] CHU Charles Nicolle, Serv Hepatogastroenterol, Rouen, France

[22] Bruxelles Univ Libre, Brussels, Belgium

[23] Univ Poitiers Hosp, Poitiers, France

[24] CHD Vendee, Serv Med Interne, La Roche Sur Yon, France

[25] Hop Univ Strasbourg, LabEx HepSYS, INSERM, U1110, INSERM U, France

[26] CHU Estaing, Pole Digestif, Clermont Ferrand, France

[27] CHU Dupuytren, Serv Hepatogastroenterol & Nutr, Limoges, France

[28] ANRS France Rech Nord Sud Sida Hiv Hepatites, Paris, France

[29] Montpellier Univ Hosp, St Eloi Hosp, Montpellier, France

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2018年 / 47卷 / 12期

关键词：

GLOMERULAR-FILTRATION-RATE; ACTING ANTIVIRAL AGENTS; C VIRUS-INFECTION; HEPATITIS-C; GENOTYPE; RECIPIENTS; RIBAVIRIN; KIDNEY; EXPERIENCE; EFFICACY;

D O I：

10.1111/apt.14639

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: In liver transplant recipients with hepatitis C virus recurrence, there is concern about renal safety of sofosbuvir-based regimens. Changes in serum creatinine or in the estimated glomerular filtration rate (eGFR) under treatment are used to look for possible renal toxicity. However, serum creatinine and eGFR are highly variable. Aim: To analyse renal function trajectory with numerous assays of serum creatinine over a long period of time. Methods: In a multicentre cohort of 139 patients, the eGFR was obtained from serum creatinine using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation. Slopes of eGFR were defined as a change in eGFR during a period divided by time. Pre-treatment, on-treatment and post-treatment periods were 9 months, 3-9 months and 4.5 months. Interactions between eGFR slopes and the pre-treatment eGFR, use of ribavirin or mycophenolate mofetil, and stage of fibrosis were addressed. On-treatment eGFR slopes were separated in tertiles. Pre- and post-treatment eGFR slopes were compared globally and according to tertiles. Results: The post-treatment eGFR slope was significantly better than pre-treatment eGFR slope (+0.18 (IQR -0.76 to +1.32) vs -0.11 (IQR -1.01 to +0.73) mL/min/1.73 m(2)/month, P=0.03) independently of the pre-treatment eGFR (P=0.99), ribavirin administration (P=0.26), mycophenolate mofetil administration (P=0.51) and stage of fibrosis (F3 and F4 vs lower stages, P=0.18; F4 vs lower stages, P=0.08; F4 Child-Pugh B and C vs lower stages, P=0.38). Tertiles of on-treatment eGFR slopes were -1.71 (IQR -2.54 to -1.48), -0.78 (IQR -1.03 to -0.36) and +0.75 (IQR +0.28 to +1.47) mL/min/1.73 m(2)/month. Pre- and post-treatment eGFR slopes were not significantly different according to tertiles (respectively, P=0.34, 0.08, 0.73). Conclusion: The eGFR varies during treatment and gives a confusing picture of the renal safety of sofosbuvir-based regimens. In contrast, longitudinal assessment of the eGFR shows a rising trajectory over longer time, meaning that these therapies are safe for the kidneys in our cohort of liver transplant recipients.

引用

页码：1682 / 1689

页数：8

共 43 条

[21] Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study
Dharancy, Sebastien
Coilly, Audrey
Fougerou-Leurent, Claire
Duvoux, Christophe
Kamar, Nassim
Leroy, Vincent
Tran, Albert
Houssel-Debry, Pauline
Canva, Valerie
Moreno, Christophe
Conti, Filomena
Dumortier, Jerome
Di Martino, Vincent
Radenne, Sylvie
De Ledinghen, Victor
D'Alteroche, Louis
Silvain, Christine
Besch, Camille
Perre, Philippe
Botta-Fridlund, Danielle
Francoz, Claire
Habersetzer, Francois
Montialoux, Helene
Abergel, Armand
Debette-Gratien, Maryline
Rohel, Alexandra
Rossignol, Emilie
Samuel, Didier
Duclos-Vallee, Jean-Charles
Pageaux, Georges-Philippe
AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (11) : 2869 - 2878
[22] Impact of Sofosbuvir-Based Regimens on Renal Function in Liver Transplant Recipients: Results of a Multicenter Study
Faisal, Nabiha
Renner, Eberhard L.
Bilodeau, Marc
Aljudaibi, Bandar
Hirsch, Geri
Yoshida, Eric M.
Hussaini, Tarana
Ghali, Peter
Congly, Stephen E.
Ma, Mang M.
Leonard, Jennifer
Cooper, Curtis
Peltekian, Kevork M.
Selzner, Nazia
Lilly, Les
HEPATOLOGY, 2015, 62 : 312A - 313A
[23] SOFOSBUVIR AND NS5A INHIBITORS WITHOUT RIBAVIRIN DURING 12 WEEKS ARE EFFICIENT TO TREAT HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION ONLY IN GENOTYPE 1. RESULTS FROM THE CO23 ANRS CUPILT STUDY
Houssel-Debry, P.
Coilly, A.
Fougerou-Leurent, C.
Jezequel, C.
Duvoux, C.
De Ledinghen, V.
Radenne, S.
Kamar, N.
Leroy, V.
Di Martino, V.
D'alteroche, L.
Canva, V.
Conti, F.
Dumortier, J.
Montialoux, H.
Lebray, P.
Botta-Fridlund, D.
Anty, R.
Moreno, C.
Silvain, C.
Besch, C.
Perre, P.
Francoz, C.
Abergel, A.
Habersetzer, F.
Debette-Gratien, M.
Rohel, A.
Diallo, A.
Rossignol, E.
Veislinger, A.
Danjou, H.
Duclos-Vallee, J. C.
Pageaux, G. P.
TRANSPLANT INTERNATIONAL, 2017, 30 : 25 - 25
[24] Sofosbuvir and NS5A inhibitors without Ribavirin during 12 weeks are efficient to treat hepatitis C recurrence after liver transplantation only in genotype 1. Results from the CO23 ANRS CUPILT study.
Houssel-Debry, Pauline
Coilly, Audrey
Fougerou-Leurent, Claire
Jezequel, Caroline
Duvoux, Christophe
de Ledinghen, Victor
Radenne, Sylvie
Kamar, Nassim
Leroy, Vincent
Di Martino, Vincent
d'Alteroche, Louis
Canva-Delcambre, Valerie
Conti, Filomena
Dumortier, Jerome
Montialoux, Helene
Lebray, Pascal
Botta-Fridlund, Danielle
Anty, Rodolphe
Moreno, Christophe
Silvain, Christine
Besch, Camille
Perre, Philippe
Francoz, Claire
Abergel, Armand
Habersetzer, Francois
Debette-Gratien, Maryline
Rohel, Alexandra
Diallo, Alpha
Rossignol, Emilie
Danjou, Helene
Veislinger, Aurelie
Duclos-Vallee, Jean-Charles
Pageaux, Georges-Philippe
HEPATOLOGY, 2016, 64 : 465A - 465A
[25] Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study
Faisal, Nabiha
Bilodeau, Marc
Aljudaibi, Bandar
Hirch, Geri
Yoshida, Eric M.
Hussaini, Trana
Ghali, Maged P.
Congly, Stephen E.
Ma, Mang M.
Lilly, Leslie B.
EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2019, 17 (01) : 59 - 63
[26] No evidence of hepatitis B virus reactivation among liver transplant recipients treated with interferon- free regimens for hepatitis C virus recurrence (ANRS CO23 CUPILT Cohort)
Mouna, Lina
Rossignol, Emilie
Tateo, Mariagrazia
Duclos-Vallee, Jean-Charles
Duvoux, Christophe
Durand, Francois
Tran, Albert
Radenne, Sylvie
Canva-Delcambre, Valerie
Houssel-Debry, Pauline
Dumortier, Jerome
Conti, Filomena
de Ledinghen, Victor
Leroy, Vincent
Kamar, Nassim
Di Martino, Vincent
Moreno, Christophe
Fridlund, Danielle M. Botta
d'Alteroche, Louis
Lebray, Pascal
perre, philippe
Besch, Camille
Silvain, Christine
Habersetzer, Francois
Debette-Gratien, Maryline
Abergel, Armando
Diallo, Alpha
Roque-Afonso, Anne Marie
Pageaux, Georges-Philippe
HEPATOLOGY, 2017, 66 : 873A - 874A
[27] Safety and efficacy of all-oral sofosbuvir-based regimens to treat HCV recurrence post-liver transplantation
Alsabbagh, Mohammed Eyad Yaseen
Hanouneh, Ibrahim A.
John, Binu V.
Guirguis, John K.
Eghtesad, Bijan
Fung, John J.
Zein, Nizar N.
Alkhouri, Naim
HEPATOLOGY, 2014, 60 : 700A - 701A
[28] Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients
Mazzitelli, Maria
Torti, Carlo
Sabatino, Jolanda
D'Ascoli, Greta Luana
Costa, Chiara
Pisani, Vincenzo
Raffetti, Elena
De Rosa, Salvatore
Strazzulla, Alessio
Foca, Alfredo
Liberto, Maria Carla
Indolfi, Ciro
HEPATOLOGY, 2017, 66 : 577A - 578A
[29] Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients
Maria Mazzitelli
Carlo Torti
Jolanda Sabatino
Greta Luana D’Ascoli
Chiara Costa
Vincenzo Pisani
Elena Raffetti
Salvatore De Rosa
Alessio Strazzulla
Alfredo Focà
Maria Carla Liberto
Ciro Indolfi
BMC Infectious Diseases, 18
[30] Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients
Mazzitelli, Maria
Torti, Carlo
Sabatino, Jolanda
D'Ascoli, Greta Luana
Costa, Chiara
Pisani, Vincenzo
Raffetti, Elena
De Rosa, Salvatore
Strazzulla, Alessio
Foca, Alfredo
Liberto, Maria Carla
Indolfi, Ciro
BMC INFECTIOUS DISEASES, 2018, 18

← 1 2 3 4 5 →